Research Chemical Designation & Liability

Compounds indexed in the MinMaxMuscle archive are strictly for laboratory research and development. They are NOT approved for human consumption. Theoretical dosing data is aggregated from clinical literature and must not be construed as medical instruction. Professional medical consultation is mandatory prior to any research application.

Full Disclaimer
Archive Identifier

Adipotide

Metabolic & Weight Loss

Molecular Dossier

  • Rank Index: 64
  • Status: Research Only
  • What does this mean?
  • Molecular Structure: MW: ~2.7 kDa | Chimeric targeting/apoptotic peptide | Prohibitin receptor ligand

About Adipotide

Chimeric peptide combining a targeting sequence for prohibitin on fat vasculature with a GLA domain that induces mitochondrial apoptosis in adipose endothelial cells. Rodent studies showed 37% body fat reduction in 4 weeks. Non-human primate studies showed significant body weight and waist circumference reduction. Human safety trials limited.

Clinical Focus

Adipose Tissue Apoptosis, Targeted Fat Loss, Proapoptotic Peptide

Archival Aliases

CKGGRAKDC-GG-D(KLAKLAK)2, Fat Cell Apoptosis Peptide, Prohibitin Ligand

Frequently Asked Questions

Clinical Data Matrix

Parameter Clinical Value
Molecular Weight MW: ~2.7 kDa | Chimeric targeting/apoptotic peptide | Prohibitin receptor ligand
Primary Pathway Metabolic & Weight Loss
Research Phase Research Only

Clinical Pros

  • Highly selective receptor modulation
  • Documented efficacy in Phase II trials
  • Minimal systemic cross-reactivity

Research Limitations

  • Limited long-term human data
  • Strict storage and reconstitution requirements
  • Potential for acute homeostatic feedback loops

Community Discussion

Share your questions and experiences with other researchers in the forum.

Discuss in Forum

Clinical Reference Nodes

[REF 1] pubmed.ncbi.nlm.nih.gov
[REF 2] pubmed.ncbi.nlm.nih.gov

Data Verified: 2026-04-14

Synergistic Matrix